Financials data is unavailable for this security.
View more
Year on year Santen Pharmaceutical Co Ltd grew revenues 8.22% from 279.04bn to 301.97bn while net income improved from a loss of 14.95bn to a gain of 26.64bn.
Gross margin | 57.92% |
---|---|
Net profit margin | 8.64% |
Operating margin | 12.33% |
Return on assets | 6.25% |
---|---|
Return on equity | 8.76% |
Return on investment | 7.77% |
More ▼
Cash flow in JPYView more
In 2024, Santen Pharmaceutical Co Ltd increased its cash reserves by 63.35%, or 36.68bn. The company earned 72.65bn from its operations for a Cash Flow Margin of 24.06%. In addition the company used 6.15bn on investing activities and also paid 34.03bn in financing cash flows.
Cash flow per share | 124.15 |
---|---|
Price/Cash flow per share | 14.37 |
Book value per share | 827.65 |
---|---|
Tangible book value per share | 600.21 |
More ▼
Balance sheet in JPYView more
Current ratio | 2.61 |
---|---|
Quick ratio | 1.97 |
Total debt/total equity | 0.1955 |
---|---|
Total debt/total capital | 0.1639 |
More ▼
Growth rates in JPY
SmartText is unavailable
Div yield(5 year avg) | 2.09% |
---|---|
Div growth rate (5 year) | 4.88% |
Payout ratio (TTM) | 23.64% |
EPS growth(5 years) | -1.60 |
---|---|
EPS (TTM) vs TTM 1 year ago | 3.72 |
More ▼